DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ortho-Cept (Desogestrel / Ethinyl Estradiol) - Published Studies

 
 



Ortho-Cept Related Published Studies

Well-designed clinical trials related to Ortho-Cept (Desogestrel / Ethinyl Estradiol)

Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. [2005.06]

Serum resistin levels in women taking combined oral contraceptives containing desogestrel or gestodene. [2004.06]

A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. [2004.04]

Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. [2003.08]

A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. [2003.06]

Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism. [2002.12]

Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive. [2002.12]

Different effects of oral contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VII. [2002.01]

Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel. [2001.09]

Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size. [2001.07]

Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate. [2001.03]

Latin american experience with two low-dose oral contraceptives containing 30 microg ethinylestradiol/75 microg gestodene and 20 microg ethinylestradiol/150 microg desogestrel. [2000.09]

A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. [2000.07]

Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. [2000.07]

Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (desogestrel/ethinyl estradiol) and ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol): a randomized clinical trial. [2000.05]

A comparative study of the effects of two oral contraceptives containing dienogest or desogestrel on the human immune system. [2000.02]

A comparative study of the effects of gestodene 60 microg/ethinylestradiol 15 microg and desogestrel 150 microg/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolism. [1999.11]

A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mu(g) ethinylestradiol and either 2 mg chlormadinone acetate or 150 mu(g) desogestrel. [1999.09]

Comparison of the effects of triphasic oral contraceptives with desogestrel or levonorgestrel on apolipoprotein A-I-containing high-density lipoprotein particles. [1999.05]

Comparative study on the acceptability of two modern monophasic oral contraceptive preparations: 30 microgram ethinyl estradiol combined with 150 microgram desogestrel or 75 microgram gestodene. [1999]

A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 micrograms ethinylestradiol and either 150 micrograms desogestrel or 75 micrograms gestodene. [1998.12]

Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene. [1998.09]

Gestodene and desogestrel do not have a different influence on concentration profiles of ethinylestradiol in women taking oral contraceptives--results of isotope dilution mass spectrometry measurements. [1998.08]

Ovarian activity in women taking an oral contraceptive containing 20 microg ethinyl estradiol and 150 microg desogestrel: effects of low estrogen doses during the hormone-free interval. [1998.07]

Ethinylestradiol 20 versus 30 micrograms combined with 150 micrograms desogestrel: a large comparative study of the effects of two low-dose oral contraceptives on the hemostatic system. [1996.08]

Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate. [1996.07]

Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris. [1996.03]

The effect of desogestrel, gestodene, and other factors on spotting and bleeding. [1996.02]

A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 20 micrograms ethinylestradiol/150 micrograms desogestrel, with respect to efficacy, cycle control and tolerance. [1995.10]

Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women. [1995.04]

Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel. [1995]

Prodrug versus drug effects of 150 micrograms desogestrel or 3-keto-desogestrel in combination with 30 micrograms ethinylestradiol on hormonal parameters: relevance of the peak serum level of 3-keto-desogestrel. [1995]

Serum distribution of two contraceptive progestins: 3-ketodesogestrel and gestodene. [1994.10]

Hemostasis profile and lipid metabolism with long-interval use of a desogestrel-containing oral contraceptive. [1994.08]

Desogestrel versus gestodene in oral contraceptives: influence on the clinical and histomorphological features of benign breast disease. [1994.05.31]

Multicenter randomized comparative trial of two low-dose triphasic combined oral contraceptives containing desogestrel or norethindrone. [1994.05]

Very low estrogen-desogestrel contraceptive in perimenopausal hormonal replacement. [1994.02]

Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone. [1994.02]

Pharmacokinetics and protein binding of 3-ketodesogestrel and gestodene in the serum of women during 6 cycles of treatment with two low dose oral contraceptives. [1993.12]

Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel. [1993.09]

Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol. [1993.09]

Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol. [1993.03]

Pharmacokinetics and serum protein binding of 3-keto-desogestrel in women during three cycles of treatment with a low-dose combination oral contraceptive. [1992.09]

A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel. [1992.06]

Contraceptives containing desogestrel or levonorgestrel have different effects on serum lipoproteins and post-heparin plasma lipase activities. [1992.02]

Oral contraceptive containing desogestrel in the maintenance of the remission of hirsutism: monthly versus bimonthly treatment. [1991.11]

Desogestrel and gestodene in oral contraceptives: 12 months' assessment of carbohydrate and lipoprotein metabolism. [1991.10]

Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives. [1991.05]

The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. [1991.04]

A comparative study on the effects of a monophasic pill containing desogestrel plus 20 micrograms ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors. [1991.01]

Comparative studies of 30 micrograms ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis, and platelets. [1990.07]

Effects of ethinyl estradiol combined with desogestrel and cyproterone acetate on glucose tolerance and insulin response to an oral glucose load: a one-year randomized, prospective, comparative trial. [1990.07]

Estrogenic effect of gestodene- or desogestrel-containing oral contraceptives on lipoprotein metabolism. [1990.07]

Protein binding of active ingredients and comparison of serum ethinyl estradiol, sex hormone-binding globulin, corticosteroid-binding globulin, and cortisol levels in women using a combination of gestodene/ethinyl estradiol (Femovan) or a combination of desogestrel/ethinyl estradiol (Marvelon) and single-dose ethinyl estradiol bioequivalence from both oral contraceptives. [1990.07]

Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study. [1990.05]

Changes in lipid metabolism during 12 months of treatment with two oral contraceptives containing 30 micrograms ethinylestradiol and 75 micrograms gestodene or 150 micrograms desogestrel. [1990.03]

Ovulation inhibitors containing cyproterone acetate or desogestrel in the treatment of hyperandrogenic symptoms. [1990]

Effect of two monophasic oral contraceptives containing gestodene or desogestrel on serum lipoprotein lipid levels. [1989.09]

Comparison of two monophasic oral contraceptives: gestodene/ethinyl estradiol versus desogestrel/ethinyl estradiol. [1989.09]

Effect of two oral contraceptives containing 30 micrograms ethinylestradiol and 75 micrograms gestodene or 150 micrograms desogestrel upon various hormonal parameters. [1988.12]

Ethinylestradiol and desogestrel, alone or in combination with two doses of estriol. Effects on plasma proteins. [1988]

Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel. [1985.04]

Well-designed clinical trials possibly related to Ortho-Cept (Desogestrel / Ethinyl Estradiol)

Extended regimens of the contraceptive vaginal ring: a randomized trial. [2005.09]

Decreased plasma sensitivity to activated protein C by oral contraceptives is associated with decreases in plasma glucosylceramide. [2005.05]

20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception. [2005.04.18]

Effects of two types of hormonal contraception--oral versus intravaginal--on the sexual life of women and their partners. [2005.04]

A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization. [2005.02]

Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials. [2005]

Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use. [2004.11]

Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. [2004.06]

Effects of hormonal contraception on bone mineral density after 24 months of use. [2004.05]

Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression. [2004.04]

The combined contraceptive vaginal ring, NuvaRing, and tampon co-usage. [2004.03]

Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. [2004.02.01]

Sex hormone--binding globulin--a surrogate marker for the prothrombotic effects of combined oral contraceptives. [2004.02]

The contraceptive vaginal ring, NuvaRing, and antimycotic co-medication. [2004.02]

Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. [2003.12]

Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. [2003.10]

A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris. [2003.05]

Efficacy of second versus third generation oral contraceptives in the treatment of hirsutism. [2003.05]

The combined contraceptive ring NuvaRing and spermicide co-medication. [2003.04]

The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. [2003.03]

Genetic polymorphisms modify the response of factor VII to oral contraceptive use: an example of gene-environment interaction. [2002.08]

Effect of second- and third-generation oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation. [2002.07]

[Ultrasonographic and lipid changes in polycystic ovary syndrome according to the type of treatment ] [2002.06]

Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. [2002.05]

Serum concentrations of markers of type I collagen metabolism in women taking monophasic oral contraceptives. [2002.02]

Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. [2002.02]

Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. [2002.01]

Effect of second and third generation oral contraceptives on lipid metabolism in the absence or presence of the factor V Leiden mutation. [2001.11]

Bone mineral density in young, hypothalamic oligoamenorrheic women treated with oral contraceptives. [2001.10]

A scheme of combined oral contraceptives for women more than 40 years old. [2001.07]

Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. [2001.05]

Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. [2000.09]

Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. [2000.07]

Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. [2000.06]

Effect of an oral contraceptive on the plasma levels of budesonide and prednisolone and the influence on plasma cortisol. [2000.04]

Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. [2000.03]

A randomized trial of oral contraceptive and hormone replacement therapy on bone mineral density and coronary heart disease risk factors in postmenopausal women. [2000.01]

Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile. [2000]

Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. [1999.12.11]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017